{"id":2201,"date":"2013-11-27T16:05:30","date_gmt":"2013-11-27T15:05:30","guid":{"rendered":"http:\/\/dev-leitat-projects-blog.pantheonsite.io\/?p=2201"},"modified":"2025-02-10T11:30:49","modified_gmt":"2025-02-10T11:30:49","slug":"therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody","status":"publish","type":"post","link":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/","title":{"rendered":"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody"},"content":{"rendered":"<p>Researchers from BIOMED Division at LEITAT Technological Center, in collaboration with the University of Barcelona, demonstrated the efficacy of a new approach for the treatment of human cancer in preclinical trials. The new strategy is based on the action of a monoclonal anti-body against S100A4, which is a key factor for tumoural growth. The blockage of S100A4 disrupts the communication of malignant cells.<\/p>\n<p>Check the full publication here:<\/p>\n<p><a href=\"http:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0072480\">http:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0072480<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers from BIOMED Division at LEITAT Technological Center, in collaboration with the University of Barcelona, demonstrated the efficacy of a new approach for the treatment of human cancer in preclinical trials. The new strategy is based on the action of a monoclonal anti-body against S100A4, which is a key factor for tumoural growth. The blockage [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2203,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[14],"tags":[25],"class_list":["post-2201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-technologies","tag-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody - Leitat Technological Center<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody - Leitat Technological Center\" \/>\n<meta property=\"og:description\" content=\"Researchers from BIOMED Division at LEITAT Technological Center, in collaboration with the University of Barcelona, demonstrated the efficacy of a new approach for the treatment of human cancer in preclinical trials. The new strategy is based on the action of a monoclonal anti-body against S100A4, which is a key factor for tumoural growth. The blockage [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/\" \/>\n<meta property=\"og:site_name\" content=\"Leitat Technological Center\" \/>\n<meta property=\"article:published_time\" content=\"2013-11-27T15:05:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-10T11:30:49+00:00\" \/>\n<meta name=\"author\" content=\"Comunicaci\u00f3n Leitat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Comunicaci\u00f3n Leitat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/\"},\"author\":{\"name\":\"Comunicaci\u00f3n Leitat\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\"},\"headline\":\"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody\",\"datePublished\":\"2013-11-27T15:05:30+00:00\",\"dateModified\":\"2025-02-10T11:30:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/\"},\"wordCount\":94,\"publisher\":{\"@id\":\"https:\/\/leitat.org\/es\/#organization\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"News\"],\"articleSection\":[\"Health technologies\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/\",\"url\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/\",\"name\":\"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody - Leitat Technological Center\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2013-11-27T15:05:30+00:00\",\"dateModified\":\"2025-02-10T11:30:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"HOME\",\"item\":\"https:\/\/leitat.org\/es\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health technologies\",\"item\":\"https:\/\/leitat.org\/es\/blog\/category\/health-technologies\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/leitat.org\/es\/#website\",\"url\":\"https:\/\/leitat.org\/es\/\",\"name\":\"Leitat Technological Center\",\"description\":\"Managing Technologies\",\"publisher\":{\"@id\":\"https:\/\/leitat.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/leitat.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/leitat.org\/es\/#organization\",\"name\":\"Leitat Technological Center\",\"url\":\"https:\/\/leitat.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"width\":226,\"height\":78,\"caption\":\"Leitat Technological Center\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\",\"name\":\"Comunicaci\u00f3n Leitat\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"caption\":\"Comunicaci\u00f3n Leitat\"},\"sameAs\":[\"https:\/\/leitat.org\"],\"url\":\"https:\/\/leitat.org\/es\/blog\/author\/comunica-wp\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody - Leitat Technological Center","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_ES","og_type":"article","og_title":"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody - Leitat Technological Center","og_description":"Researchers from BIOMED Division at LEITAT Technological Center, in collaboration with the University of Barcelona, demonstrated the efficacy of a new approach for the treatment of human cancer in preclinical trials. The new strategy is based on the action of a monoclonal anti-body against S100A4, which is a key factor for tumoural growth. The blockage [&hellip;]","og_url":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/","og_site_name":"Leitat Technological Center","article_published_time":"2013-11-27T15:05:30+00:00","article_modified_time":"2025-02-10T11:30:49+00:00","author":"Comunicaci\u00f3n Leitat","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Comunicaci\u00f3n Leitat","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#article","isPartOf":{"@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/"},"author":{"name":"Comunicaci\u00f3n Leitat","@id":"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131"},"headline":"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody","datePublished":"2013-11-27T15:05:30+00:00","dateModified":"2025-02-10T11:30:49+00:00","mainEntityOfPage":{"@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/"},"wordCount":94,"publisher":{"@id":"https:\/\/leitat.org\/es\/#organization"},"image":{"@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage"},"thumbnailUrl":"","keywords":["News"],"articleSection":["Health technologies"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/","url":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/","name":"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody - Leitat Technological Center","isPartOf":{"@id":"https:\/\/leitat.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage"},"image":{"@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage"},"thumbnailUrl":"","datePublished":"2013-11-27T15:05:30+00:00","dateModified":"2025-02-10T11:30:49+00:00","breadcrumb":{"@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/leitat.org\/es\/blog\/therapeutic-targeting-of-tumor-growth-and-angiogenesis-with-a-novel-anti-s100a4-monoclonal-antibody\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"HOME","item":"https:\/\/leitat.org\/es\/home\/"},{"@type":"ListItem","position":2,"name":"Health technologies","item":"https:\/\/leitat.org\/es\/blog\/category\/health-technologies\/"},{"@type":"ListItem","position":3,"name":"Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody"}]},{"@type":"WebSite","@id":"https:\/\/leitat.org\/es\/#website","url":"https:\/\/leitat.org\/es\/","name":"Leitat Technological Center","description":"Managing Technologies","publisher":{"@id":"https:\/\/leitat.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leitat.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/leitat.org\/es\/#organization","name":"Leitat Technological Center","url":"https:\/\/leitat.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","width":226,"height":78,"caption":"Leitat Technological Center"},"image":{"@id":"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131","name":"Comunicaci\u00f3n Leitat","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","caption":"Comunicaci\u00f3n Leitat"},"sameAs":["https:\/\/leitat.org"],"url":"https:\/\/leitat.org\/es\/blog\/author\/comunica-wp\/"}]}},"_links":{"self":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/2201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/comments?post=2201"}],"version-history":[{"count":1,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/2201\/revisions"}],"predecessor-version":[{"id":63628,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/2201\/revisions\/63628"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/media?parent=2201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/categories?post=2201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/tags?post=2201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}